We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
TOY | Toys R Us ANZ Ltd | 0.095 | 0.086 | 955.56% | 66,642 | 31 |
BP8 | BPH Global Ltd | 0.004 | 0.003 | 300.00% | 3,422,941 | 19 |
JATO | Jatcorp Limited | 0.004 | 0.003 | 300.00% | 414,355 | 6 |
FTL | Firetail Resources Ltd | 0.1125 | 0.0665 | 144.57% | 25,368,931 | 761 |
BEO | Beonic Ltd | 0.03 | 0.008 | 36.36% | 269,500 | 7 |
GCM | Green Critical Minerals Ltd | 0.004 | 0.001 | 33.33% | 608,675 | 3 |
VPR | Volt Power Group Limited | 0.002 | 0.0005 | 33.33% | 20,498,641 | 12 |
EUROB | European Lithium Limited | 0.004 | 0.001 | 33.33% | 372,000 | 3 |
OSX | Osteopore Limited | 0.07 | 0.017 | 32.08% | 34,608,080 | 1,131 |
MPP | Metro Performance Glass Limited | 0.083 | 0.017 | 25.76% | 94,812 | 2 |
SIX | Sprintex Ltd | 0.045 | 0.009 | 25.00% | 1,964,199 | 77 |
WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, is pleased to report seeing continued penetration into the $296 billion wireless audio market fueled by interest in its WiSA E software.
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
No Shareholder Action Required at This TimeWASHINGTON, June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,901.08 | -174.94 | -0.25% | 1.39T | 3,198,972,379 |
ETH | Ethereum | 3,825.88 | -38.33 | -0.99% | 462.15B | 1,918,607,249 |
BNB | Binance Coin | 701.68 | 3.03 | 0.43% | 110.47B | 516,242,217 |
USDT | Tether USD | 0.99958 | -0.00042 | -0.04% | 97.8B | 225,747,420 |
SOL | Solana | 171.97 | -1.47 | -0.85% | 76.1B | 518,987,776 |
STETH | stETH | 3,801.34 | -61.33 | -1.59% | 37.71B | 4,753,346 |
XRP | Ripple | 0.5251 | -0.0005 | -0.10% | 28.69B | 234,230,763 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 860,372,008 |
TONCOIN | Wrapped TON Coin | 7.38 | 0.209603 | 2.92% | 25.72B | 108,895,296 |
DOGE | Dogecoin | 0.16188 | -0.0012 | -0.74% | 23.3B | 198,614,661 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions